Picture of Allergy Therapeutics logo

AGY Allergy Therapeutics News Story

gb flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapFalling Star

REG - Allergy Therapeutics - Total Voting Rights

For best results when printing this announcement, please click on link below:

RNS Number : 3575A  Allergy Therapeutics PLC  01 February 2022

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")


Total Voting Rights and Block Listing Return



Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial
biotechnology company specialising in allergy vaccines, announces
that pursuant to its block admission facility, details of which were
announced on 21 November 2017, it has recently issued 401,850 ordinary shares
of 0.1 pence each ("Ordinary Shares") in satisfaction of the exercise of share
options. The new Ordinary Shares rank pari passu with the Company's existing

In accordance with DTR 5.6.1 of the Financial Conduct Authority's Disclosure
Guidance and Transparency Rules, as at 31 January 2022, the Company had
643,998,996 Ordinary Shares in issue. There are no shares held in treasury.
The total number of voting rights in the Company is therefore 643,998,996.

The above figure of 643,998,996 may be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company under the FCA's Disclosure Guidance and
Transparency Rules.

Block Listing Return


Allergy also makes the following notification pursuant to AIM Rule 29 and
Schedule Six of the AIM Rules for Companies, regarding its existing block
listing (excluding the additional block listing applications above and those
block listings that have now been cancelled):


 Name of applicant:                                                                ALLERGY THERAPEUTICS PLC
 Name of scheme:                                                                   Allergy Therapeutics plc 2013 Long Term Incentive Plan
 Period of return:                        From:                                    31 January 2021             To:                         31 January 2022
 Number and class of share(s) (amount of stock / debt securities) originally       10,000,000 ordinary shares of 0.1p each in the Company admitted to trading on
 listed and the date of admission:                                                 24 November 2017
 Balance of unallotted securities under scheme(s) from previous return:            3,325,604

 Plus:  The amount by which the block scheme(s) has been increased since the       7,000,000
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period:        3,206,832
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        7,118,772


 Name of contact:              Sara Goldsbrough
 Telephone number of contact:  +44 (0) 7966 165719



For further information, please contact:


Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer


Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking


Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi



Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com (mailto:christina@sternir.com)





Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company
focussed on the treatment and diagnosis of allergic disorders, including
aluminium free immunotherapy vaccines that have the potential to cure disease.
The Group sells proprietary and third-party products from its subsidiaries in
nine major European countries and via distribution agreements in an additional
ten countries. Its broad pipeline of products in clinical development includes
vaccines for grass, tree and house dust mite, and peanut allergy vaccine in
pre-clinical development. Adjuvant systems to boost performance of vaccines
outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is
headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art
MHRA-approved manufacturing facilities and laboratories. The Group, which has
achieved over 9% compound annual growth since formation, employs c.600
employees and is listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com/)  .


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)

Recent news on Allergy Therapeutics

See all news